<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number 000-09428
NOTIFICATION OF LATE FILING
(Check One): [X] Form 10-K [ ] Form 11-K [ ] Form 20-F [ ] Form 10-Q
[ ] Form N-SAR
For Period Ended: March 31, 1999
------------------------------
[ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For the Transition Period Ended:
----------------------------------------------
Read attached instruction sheet before preparing form. Please print or
type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify item(s) to which the notification relates:
---------------------------
- ------------------------------------------------------------------------------
Part I. Registrant Information
Full name of registrant SpectruMedix Corporation
---------------------------
Former name if applicable
- ------------------------------------------------------------------------------
Address of principal executive office (Street and number)
2124 Old Gatesburg Road
- ------------------------------------------------------------------------------
City, State and Zip Code State College, Pennsylvania 16803
----------------------------------------------------
<PAGE>
Part II. Rule 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box.)
[ ] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[ X ] (b) The subject annual report, semi-annual report, transition report on
Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on
or before 15th calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule 12b-
25(c) has been attached if applicable.
Part III. Narrative
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-
Q, N-SAR or the transition report portion thereof could not be filed within the
prescribed time period. (Attach extra sheets if needed).
Effective January 28, 1999, Bernard Sonnenschein, treasurer and
secretary of SpectruMedix Corporation (the "Company"), resigned from his
positions with the Company. Mr. Sonnenschein was solely responsible for
completing the work related to the Company's financial and regulatory
reporting. His resignation has required much reorganization within the
Company with respect to such financial and regulatory reporting. The
Company has been required to arrange with other employees of the Company,
previously only marginally involved in this work, as well as members of the
Company's professional team, to take over and distribute among themselves
the duties of Mr. Sonnenschein. The Company's Annual Report on Form 10-KSB
for the fiscal year ended March 31, 1999 (the "10-KSB") is the first Annual
Report on Form 10-KSB required to be filed since Mr. Sonnenschein's
departure. The Company has encountered many unexpected difficulties in
preparing the 10-KSB as a result of Mr. Sonnenschein's departure, and these
difficulties have delayed substantially the Company's ability to timely
file the 10-KSB. Consequently, the Company will be unable to file the Form
10-KSB within the proscribed period and hereby requests an extension
pursuant to Rule 12b-25 promulgated under the Securities and Exchange Act
of 1934, as amended, until July 14, 1999, a date which is within 15
calendar days of the required filing date.
2
<PAGE>
Part IV. Other Information
(1) Name and telephone number of person to contact in regard to this
notification.
Karl Fazler (814) 867-7600
-------------------- ------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Sections 13 and 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
[ X ] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
[ ] Yes [ X ] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
SpectruMedix Corporation
- -------------------------------------------------------------------------------
(Name of registrant as specified in charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: June 28, 1999 By: /s/ Joseph K. Adlerstein
--------------- -------------------------
Name: Joseph K. Adlerstein
Title: President and Chief Executive Officer
3
